ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is Coconut Oil Healthy? (The American Heart Association Doesn’t Think So)

American Heart Association Renders Itself Obsolete With 1960s Dietary Advice on Coconut Oil

Ginger Fights Obesity

Health Benefits of Artichokes

Putting the Spotlight on Coriander Seed Oil

Migraines? Powdered Ginger May Help

Are Americans Really Getting Too Much Vitamin D? A Critical Look at Recent Media Warnings

Eating more vegetable protein may protect against early menopause

Vitamin C and antibiotics: A new one-two 'punch' for knocking-out cancer stem cells

German Chamomile Oil: A Versatile Essential Oil You Should Have at Home

Print Page
Email Article

UCSF begins study testing antiviral drug tenofovir to prevent HIV infection

  [ 25 votes ]   [ Discuss This Article ] • September 18, 2003

UCSF researchers have been funded by the National Institutes of Health to study the antiretroviral drug tenofovir as a potential pre-exposure prophylaxis in Cambodia among high-risk, HIV-uninfected women
UCSF researchers have been funded by the National Institutes of Health to study the antiretroviral drug tenofovir as a potential pre-exposure prophylaxis in Cambodia among high-risk, HIV-uninfected women. The research will look at safety and effectiveness of the drug in preventing the acquisition of HIV.

"With both a vaccine and a microbicide many years down the road, we are hoping that this once-a-day pill--a potent, low toxicity medication used in anti-HIV combination therapy--can be taken by uninfected people at high risk for HIV infection and will keep them from becoming infected," said study principal investigator, Kimberly Page Shafer, PhD, MPH, assistant professor of medicine at the UCSF Center for AIDS Prevention Studies (CAPS).

Although studies of tenofovir to prevent HIV transmission in animals have been promising, the effectiveness of this drug for preventing HIV-1 transmission in people is not known and will be evaluated in the planned research. The study will recruit 800 adult HIV-uninfected women who are at high risk for HIV infection. The study will be a randomized, double blind clinical trial with participants chosen at random to receive either tenofovir or a placebo.

Participants will take one pill a day for 12 months. At the beginning and once a month during the trial, study subjects will receive counseling to reduce risky behavior, free condoms, and free screening and treatment of sexually transmitted infections.

Participants will be tested monthly for HIV and those who become infected during the study will be referred to an HIV treatment clinic for comprehensive care, including anti-HIV therapy if medically indicated. Effectiveness will be determined by comparing HIV infection rates between the group taking tenofovir and the one taking the placebo.

Study participants will be monitored for drug safety and adverse effects. Drug safety will be examined by comparing the occurrence of side effects in the group taking tenofovir with the one taking placebo.

The study will be conducted under the auspices of the Kingdom of Cambodia's Ministry of Health's National Center for HIV/AIDS, Dermatology and STDs in collaboration with researchers from UCSF and the University of New South Wales, Australia (UNSW). The study's grant award is for three years.

Other investigators for the study from UCSF are Robert M. Grant, MD, MPH, assistant investigator at the Gladstone Institute for Virology and Immunology, and UCSF assistant professor of medicine and Krysia Lindan, MD, UCSF associate professor of epidemiology. Margery Lazarus, PhD, MPH, medical anthropologist at UCSF CAPS, will lead formative social research for the study.

Funding for the study comes from two sources. NIH is funding UCSF, and the Bill and Melinda Gates Foundation is funding UNSW. Gilead Inc., the manufacturer, is providing placebo and tenofovir at cost (per an arrangement for developing countries, including Cambodia), and no other support or assistance.

Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil FibroSleep™ Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

NAD+ Ignite with Niagen

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Safely Burn Away Body Fat Safely Burn Away Body Fat
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
Relief for Dry, Itchy Skin Caused by Fibromyalgia Relief for Dry, Itchy Skin Caused by Fibromyalgia
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map